5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB

Pharmacology Biochemistry and Behavior

Volumn 63, Issue 2, 1999, Pages 237-243

  O'Neill, Michael F ^a   Heron Maxwell, Claire L ^a   Shaw, Gillian ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

5 HT2; C APB; D1 agonist; Hyperlocomotion; MK 801; Psychostimulants

Indexed keywords

3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMPHETAMINE; COCAINE; DIZOCILPINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RITANSERIN; SEROTONIN 2 ANTAGONIST; SEROTONIN 2 RECEPTOR; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; BENZAZEPINE DERIVATIVE; DIZOCILPINE MALEATE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOROBENZENE; INDOLE DERIVATIVE; PIPERIDINE DERIVATIVE; SEROTONIN ANTAGONIST; SK&F 82958;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HYPERACTIVITY; LOCOMOTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; DRUG EFFECT; DRUG INTERACTION; MOTOR ACTIVITY;

AMINOPYRIDINES; AMPHETAMINE; ANIMALS; BENZAZEPINES; COCAINE; DIZOCILPINE MALEATE; DOPAMINE AGONISTS; DRUG INTERACTIONS; FEMALE; FLUOROBENZENES; INDOLES; MICE; MOTOR ACTIVITY; PIPERIDINES; RITANSERIN; SEROTONIN ANTAGONISTS;

EID: 0032588208     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00240-8     Document Type: Article

References (40)

1. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14:1996;87-96.
2. 2A receptor antagonist MDL100907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse - Implications for psychosis. J. Neural Transm. [Gen. Sect.]. 100:1995;225-237.
3. Carlsson M., Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural Transm. 75:1989;221-226.
4. 2 dopamine receptor classification and its functional implications Synapse. 1:1987;347-388.
5. Clineschmidt B.V., Martin G.E., Bunting P.R., Papp A.L. Central sympathomimetic activity of (+)-5-methol-10,11-dihydro-5H-ibenzo[a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev. Res. 2:1982;135-145.
6. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., Dunn R.W. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviours. Psychopharmacology (Berlin). 120:1995;67-74.
7. Coward D.M., Imperato A., Urwyler S., White T.G. Biochemical and behavioural properties clozapine. Psychopharmacology (Berlin). 99:1989;S6-S12.
8. 2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind study Br. J. Psychiatry. 163:1993;451-455.
9. Fitton A., Heel R.C. Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia Drugs. 40:1990;722-747.
10. Freed W.J., Bing L.A., Wyatt R.J. Effects of neuroleptics on phencyclidine (PCP)-induced locomotor stimulation in mice. Neuropharmacology. 23:1984;175-181.
11. Giannini A.J., Nageotte C., Loiselle R.H., Malone D.A., Price W.A. Comparison of chlorpromazine, haloperidol and pimozide in the treatment of phencyclidine psychosis. J. Toxicol. Clin. Toxicol. 22:1985;573-579.
12. Gleason S.D., Shannon H.E. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berlin). 129:1997;79-84.
13. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46:1994;157-203.
14. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
15. 2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther. 277:1996;968-981.
16. Kelly P.H., Seviour P.W., Iversen S.D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res. 94:1975;507-522.
17. 2C receptor antagonist. Neuropharmacology. 36:1997;609-620.
18. 2 receptors, roles and regulation. Whitiker-Azmitia P.M., Peroutka S. The neuropharmacology of serotonin, vol. 600. 1990;183-193 Annals of the New York Academy of Sciences, New York.
19. Liljequist S., Ossowska K., Grabowska-Anden M., Anden N.-E. Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice. Eur. J. Pharmacol. 195:1991;55-61.
20. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry. 151:1994;825-835.
21. 2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. J. Neural Transm. 104:1997;561-564.
22. Meltzer H.Y., Matsubara S., Lee J.-C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp.Ther. 251:1989;238-246.
23. 2A antagonist. Behav. Brain Res. 73:1996;163-167.
24. Nabeshima T., Ishikawa K., Yamaguchi K., Furukawa H., Kameyama T. Phencyclidine-induced head-weaving observed in mice after ritanserin treatment. Eur. J. Pharmacol. 139:1987;171-178.
25. O'Boyle K.M., Gaitanopoulos D.E., Brenner M., Waddington J.L. Agonist and antagonist properties of benzazepine and thienopyridine derivatives at the D1 dopamine receptor. Neuropharmacology. 28:1989;401-405.
26. 2A antagonist for the treatment of schizophrenia. Early indication of safety and clinical activity in schizophrenic patients CINP Proc. PT. 10052:1998;377.
27. 2 receptor antagonists on hyperactivity, c-fos and hsp-70 induced by dizocilpine (MK-801) in mice. J. Psychopharmacol. 11S:1997;A79.
28. O'Neill M.F., Heron-Maxwell C., Shaw G. Dopamine receptor stimulation is not required for the expression of MK-801-induced hyperlocomotion in mice. Behav. Pharmacol. 9(Suppl. 9):1998;S69.
29. 2 receptors exert a state-dependent regulation of dopaminergic function. Studies with MDL 100,907 and the amphetamine analogue, 3,4,-methylenedioxymethamphetamine Eur. J. Pharmacol. 223:1992;65-74.
30. 2A receptor blockade J. Pharmacol. Exp. Ther. 277:1996;1541-1549.
31. 2A receptors in antipsychotic activity. Life Sci. 56:1995;2209-2222.
32. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1:1987;133-152.
33. Segal D.S., Schuckit M.A. Animal models of stimulant-induced psychosis. Creese I. Stimulants. neurochemical, behavioural and clinical perspectives:1983;131-167 Raven Press, New York.
34. 2 receptor antagonist MDL 100907 as a putative atypical antipsychotic. Behavioral, electorophysiological and neurochemical studies J. Pharmacol. Exp. Ther. 266:1993;684-691.
35. 2 receptor antagonists. Potential for treatment of psychiatric disorders CNS Drugs. 7:1997;388-409.
36. Strauss W.H., Klieser E. Psychotropic effects of ritanserin, a selective S2 antagonist. An open study Eur. Neuropsychopharmacol. 1:1991;101-105.
37. Targum S., Zborowski J., Henry M., Schmitz P., Sebree T., Wallin B. Efficacy and safety of sertindole in two double-blind, placebo-controlled trials of schizophrenic patients. Eur. Neuropsychopharmacol. 5:1995;348.
38. Tollefson G.D., Beasley C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., Graffeo K.A., Thieme M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders. Results of an international collaborative trial Am. J. Psychiatry. 154:1997;457-465.
39. Westerink B.H.C. Brain microdialysis and its application for the study of animal behaviour. Behav. Brain Res. 70:1995;103-124.
40. Wise R., Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol. Rev. 94:1987;469-492.